Literature DB >> 29549160

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.

Pedro Berraondo1,2,3, Iñaki Etxeberria1,2, Mariano Ponz-Sarvise2,4, Ignacio Melero5,2,3,4.   

Abstract

IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. Clin Cancer Res; 24(12); 2716-8. ©2018 AACRSee related article by Hu et al., p. 2920. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29549160     DOI： 10.1158/1078-0432.CCR-18-0381

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  26 in total

1.  Using viral vectors to deliver local immunotherapy to glioblastoma.

Authors:  Alexander F Haddad; Jacob S Young; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2021-02       Impact factor: 4.047

2.  Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion.

Authors:  Avishai Shemesh; Harry Pickering; Kole T Roybal; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-06-27       Impact factor: 17.579

3.  Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy.

Authors:  Douglas S Jones; Jonathan D Nardozzi; Katharine L Sackton; Gulzar Ahmad; Esben Christensen; Lars Ringgaard; De-Kuan Chang; Ditte E Jaehger; Jacob V Konakondla; Martin Wiinberg; Kate L Stokes; Alvin Pratama; Karsten Sauer; Thomas L Andresen
Journal:  Sci Adv       Date:  2022-04-27       Impact factor: 14.957

Review 4.  CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.

Authors:  Jing Yuan Tan; Muhammed Haiqal Low; Yunxin Chen; Francesca Lorraine Wei Inng Lim
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 5.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

6.  4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.

Authors:  Marcelo M Rodríguez; Esteban Fiore; Juan Bayo; Catalina Atorrasagasti; Mariana García; Agostina Onorato; Luciana Domínguez; Mariana Malvicini; Guillermo Mazzolini
Journal:  Mol Ther       Date:  2018-09-18       Impact factor: 11.454

7.  Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells.

Authors:  Caleb R Glassman; Yamuna Kalyani Mathiharan; Kevin M Jude; Leon Su; Ouliana Panova; Patrick J Lupardus; Jamie B Spangler; Lauren K Ely; Christoph Thomas; Georgios Skiniotis; K Christopher Garcia
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

8.  Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Authors:  Xuqing Zhang; Mengyao Luo; Shamael R Dastagir; Mellissa Nixon; Annie Khamhoung; Andrea Schmidt; Albert Lee; Naren Subbiah; Douglas C McLaughlin; Christopher L Moore; Mary Gribble; Nicholas Bayhi; Viral Amin; Ryan Pepi; Sneha Pawar; Timothy J Lyford; Vikram Soman; Jennifer Mellen; Christopher L Carpenter; Laurence A Turka; Thomas J Wickham; Tiffany F Chen
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

Review 9.  Radiotherapy in Combination With Cytokine Treatment.

Authors:  Ondrej Palata; Nada Hradilova Podzimkova; Eva Nedvedova; Alexandra Umprecht; Lenka Sadilkova; Lenka Palova Jelinkova; Radek Spisek; Irena Adkins
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

Review 10.  Beyond immune checkpoint blockade: emerging immunological strategies.

Authors:  Shawn P Kubli; Thorsten Berger; Daniel V Araujo; Lillian L Siu; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2021-03-08       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.